Adoptive T‐cell therapy (ACT) is a potent and flexible cancer treatment modality that can
induce complete, durable regression of certain human malignancies. Long‐term follow‐up …

Adoptive T-cell therapy can target and kill widespread malignant cells thereby inducing
durable clinical responses in melanoma and selected other malignances. However, many …

Although mutations may represent attractive targets for immunotherapy, direct identification
of mutated peptide ligands isolated from human leucocyte antigens (HLA) on the surface of …

Purpose: Immunotherapeutic agents produce antitumor effects by inducing cancer-specific
immune responses or by modifying native immune processes. Resulting clinical response …

The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to
develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on …

With the recent developments of adoptive T cell therapies and the use of new monoclonal
antibodies against the immune checkpoints, immunotherapy is at a turning point. Key …

Abstract Purpose: In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well
tolerated and effectively raised HER2-specific immunity in patients with breast cancer …

Background This phase II study evaluated the safety and activity of ipilimumab, a fully
human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced …

Unlike chemotherapy, which acts directly on the tumor, cancer immunotherapies exert their
effects on the immune system and demonstrate new kinetics that involve building a cellular …

Cancer testis antigens (CTA) are a large family of tumor-associated antigens expressed in
human tumors of different histological origin, but not in normal tissues except for testis and …